Sign inJoin waitlistJoin the waitlist

Paul Feuerstadt

Associate Clinical Professor · Yale School of Medicine

Credentials: · · · ·

History

Yale School of Medicine
Present

Research

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
New England Journal of Medicine · 2022 · First of 23 authors · 459 citations
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent…
Drugs · 2022 · Last of 15 authors · 254 citations
ACG clinical guideline: epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia (CI)
The American Journal of Gastroenterology · 2015 · 233 citations

Sahil Khanna
20 papers
Lawrence Brandt
19 papers
Jessica Allegretti
15 papers
MB
Mena Boules
8 papers
Olga Aroniadis
8 papers · 2 as a fellow
Erik Dubberke
7 papers
WK
Whitfield Knapple
7 papers
BM
Barbara Mcgovern
6 papers
CK
Colleen Kelly
6 papers
Anthony Lembo
5 papers
Charles Berenson
5 papers
Darrell Pardi
5 papers

Clinical trials

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2026–2031
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2032
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2024–2028
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Site PI · Recruiting · Phase 4
Takeda
2024–2027